Praxis Precision Medicines (PRAX) Misses Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts PRAX Hot Sheet
Join SI Premium – FREE
Praxis Precision Medicines (NASDAQ: PRAX) reported Q2 EPS of ($3.31), $0.06 worse than the analyst estimate of ($3.25).
For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Trump highlights ibogaine development push, Psyence BioMed responds
- La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
